Update for surgeons on novel induction treatments for acute severe inflammatory bowel disease associated colitis.
Timothy LevarMichael JohnstonNik S DingCorina C BehrenbruchPublished in: ANZ journal of surgery (2024)
JAK-inhibitors and IL-23p19 inhibitors were found to be the most effective agents for inducting remission following failure of standard of care treatment. A significant proportion of patients did not respond, highlighting the inherent challenge in optimizing treatment for moderate to severe IBD-associated colitis. More robust study designs and comparator trials are required.
Keyphrases
- ulcerative colitis
- end stage renal disease
- early onset
- quality improvement
- newly diagnosed
- ejection fraction
- chronic kidney disease
- palliative care
- liver failure
- prognostic factors
- intensive care unit
- peritoneal dialysis
- rheumatoid arthritis
- systemic lupus erythematosus
- disease activity
- patient reported outcomes
- respiratory failure
- acute respiratory distress syndrome